

## Press Release

### Orexo to Present at the Annual Biotech Showcase Conference, San Francisco

**Uppsala, Sweden, December 19, 2016** – Orexo AB (publ.), announced today that it will present at the 9<sup>th</sup> Annual Biotech Showcase Conference being held January 9-11, 2017 in San Francisco, CA.

Nikolaj Sørensen, President and CEO of Orexo AB, will present the business, focusing on the driving forces behind the global opioid addiction treatment market, the development of Zubsolv® in the US and the progress towards launching in the rest of the world. An overview will also be given of Orexo's pipeline of innovative product development programs and the company's recent strong financial development.

**Event:** 9<sup>th</sup> Annual Biotech Showcase Conference  
**Date:** Monday, January 9, 2017  
**Time:** 11:00 am (Pacific Time)  
**Location:** Room 3 (Ballroom Level), Parc 55 Hotel, San Francisco, CA

If you would like to get an update about Orexo today please visit [www.orexo.com](http://www.orexo.com) for the most recent investor presentations, financial reports and our investor dialogue. In addition a fresh interview with Nikolaj Sørensen is available at [www.orexo.com](http://www.orexo.com).

#### For more information please contact:

##### Orexo AB (publ.)

Lena Wange, IR & Communications Manager  
Tel: +46 18 780 88 00  
Email: [ir@orexo.com](mailto:ir@orexo.com)

Tirth Patel, Edison Advisors  
Tel: +1 646 653 7035  
Email: [tpatel@edisongroup.com](mailto:tpatel@edisongroup.com)

#### About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit [www.orexo.com](http://www.orexo.com) or follow us on [Twitter](#) or [LinkedIn](#). For further information about Zubsolv in the US, please visit [www.zubsolv.com](http://www.zubsolv.com).

*The information was submitted for publication at 4:15pm CET, December 19, 2016*